Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. (Q27853059)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.	scientific article

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. (English)

1 reference

PubMed publication ID

13 November 2016

0 references

0 references

1 reference

based on heuristic

inferred from title

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Sai-Hong Ignatius Ou

17

object named as

Sai-Hong Ignatius Ou

0 references

object named as

Leena Gandhi

2

0 references

author name string

Shirish M Gadgeel

1

0 references

Gregory J Riely

3

0 references

Alberto A Chiappori

4

0 references

Howard L West

5

0 references

Michele C Azada

6

0 references

Peter N Morcos

7

0 references

Ruey-Min Lee

8

0 references

Linta Garcia

9

0 references

Li Yu

10

0 references

Frederic Boisserie

11

0 references

Laura Di Laurenzio

12

0 references

Sophie Golding

13

0 references

Jotaro Sato

14

0 references

Shumpei Yokoyama

15

0 references

Tomohiro Tanaka

16

0 references

publication date

September 2014

0 references

Lancet Oncology Commission

0 references

15

0 references

10

0 references

1119-28

0 references

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70362-6

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853059&oldid=1541401662"